179 related articles for article (PubMed ID: 3284316)
1. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.
Kopelman HA; Woosley RL; Lee JT; Roden DM; Echt DS
Am J Cardiol; 1988 May; 61(13):1006-11. PubMed ID: 3284316
[TBL] [Abstract][Full Text] [Related]
2. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Kus T; Campa MA; Nadeau R; Dubuc M; Kaltenbrunner W; Shenasa M
Am Heart J; 1992 Jan; 123(1):82-9. PubMed ID: 1729853
[TBL] [Abstract][Full Text] [Related]
4. Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease.
Martínez-Rubio A; Shenasa M; Chen X; Wichter T; Breithardt G; Borggrefe M
Am J Cardiol; 1994 Feb; 73(5):357-60. PubMed ID: 7509121
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
7. [QT time and the ventricular refractory period in programmed electrical stimulation of the heart in patients with ventricular and supraventricular tachycardias--effect of sotalol].
Wehr M
Z Kardiol; 1986 Dec; 75(12):744-50. PubMed ID: 3825224
[TBL] [Abstract][Full Text] [Related]
8. Rapid intravenous infusion of d-1 sotalol: time to onset of effects on ventricular refractoriness, and safety.
Ho DS; Zecchin RP; Cooper MJ; Richards DA; Uther JB; Ross DL
Eur Heart J; 1995 Jan; 16(1):81-6. PubMed ID: 7737227
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic evaluation of pirmenol for sustained ventricular tachycardia secondary to coronary artery disease.
Easley AR; Mann DE; Reiter MJ; Sakun V; Sullivan SM; Magro SA; Luck JC; Wyndham CR
Am J Cardiol; 1986 Jul; 58(1):86-9. PubMed ID: 3728337
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Kuchar DL; Garan H; Venditti FJ; Finkelstein D; Rottman JN; McComb J; McGovern BA; Ruskin JN
Am J Cardiol; 1989 Jul; 64(1):33-6. PubMed ID: 2741811
[TBL] [Abstract][Full Text] [Related]
11. [Electrophysiologic effect of sotalol in supraventricular tachycardias].
Borggrefe M; Breithardt G
Z Kardiol; 1985 Sep; 74(9):506-11. PubMed ID: 4060828
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
Sahar DI; Reiffel JA; Bigger JT; Squatrito A; Kidwell GA
Am Heart J; 1989 Mar; 117(3):562-8. PubMed ID: 2919535
[TBL] [Abstract][Full Text] [Related]
13. Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram.
Steinbeck G; Bach P; Haberl R
J Am Coll Cardiol; 1986 Oct; 8(4):949-58. PubMed ID: 3760368
[TBL] [Abstract][Full Text] [Related]
14. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
15. Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.
Jordaens LJ; Palmer A; Clement DL
Eur Heart J; 1989 Mar; 10(3):218-26. PubMed ID: 2707270
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia.
Senges J; Lengfelder W; Jauernig R; Czygan E; Brachmann J; Rizos I; Cobbe S; Kübler W
Circulation; 1984 Mar; 69(3):577-84. PubMed ID: 6692518
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
18. Sotalol in patients with Wolff-Parkinson-White syndrome.
Kunze KP; Schlüter M; Kuck KH
Circulation; 1987 May; 75(5):1050-7. PubMed ID: 3568305
[TBL] [Abstract][Full Text] [Related]
19. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.
Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN
Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711
[TBL] [Abstract][Full Text] [Related]
20. Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
Brachmann J; Senges J; Lengfelder W; Jauernig R; Rizos I; Czygan E; Cobbe SM; Kübler W
Eur Heart J; 1985 Nov; 6 Suppl D():171-4. PubMed ID: 3936715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
